Johnson and Johnson are expected to reduce their commitment to delivering 10 million doses soon.By the end of February for carrying less than 4 million after expecting emergency use approval from the Food and Drug Administration.
The revelation of the deficiencies made by Johnson and Johnson is the first public measure of exactly how far the pharmaceutical company has lagged behind its production targets. Johnson and Johnson promised to deliver another 25 million by the end of March.
“We will have 20 million doses of the vaccine available by the end of March and we are ready to send about 4 million doses of our vaccine, immediately after authorization of use,” said ship cutters Richard Nettles, Johnson and Johnson. The subsidiary company Johnson’s vice president of medical affairs, the House Energy and Commerce Committee, said in a hearing Tuesday.
“The company believes in our plan to deliver 100 crore doses by the end of June,” he said.
As a single dose of the vaccine, which can be stored at standard refrigerator temperatures for three months, Johnson and Johnson’s candidate were compared in the U.S. vaccine effort, despite its slightly lower efficacy. Modern.
“It is a very simple vaccine to carry and administer; it does not have all these complex requirements, especially like Pfizer, which is a much more delicate vaccine. One dose, you get, you do. These are the health officials of the state and territories. “I want the vaccine,” said Dr. Marcus Plessia, chief medical officer.
While the vaccine is reasonably simple, states may be hampered in deciding which sites to prefer for standard doses or how to handle residents in hopes of obtaining a vaccine. Some of these guides may come this week to discuss Johnson & Johnson’s version, followed by the Advisory Committee on Immunization Control and Prevention, the Advisory Committee on the Immune System.
“I think there is a sense in many jurisdictions that it would be great if this vaccine came with very specific recommendations on who should get it and how to use it,” Plassia said.
Even states don’t yet know how much Johnson and Johnson doses they should have. The Biden administration expects to be able to allocate 2 million doses to jurisdictions next week.
Johnson and Johnson and federal officials both admitted for weeks that the company had faced setbacks.U.S. In, the administration asks .
Last year, states were given a definite allocation of both Pfizer and Moderna vaccines weeks before FDA authorization.
“We want to be ready when the EU approves. It’s not going to come against the EU, it’s just making sure we have everything locked up so that when the EU makes a decision, the delivery to the American people is immediate within 24 hours,” General Trump said. Gus Parna, head of the administration’s vaccine distribution effort, told reporters last year.
By comparison, earlier this week, Biden administration officials refused to give Johnson and Johnson the exact number of doses they expected, less than what states should expect allocations. Asked if certain doses would be set aside for pharmacies or other federal programs, the administration said Monday it was waiting to finalize its strategy after weighing in on the FDA and CDC.
“Once we understand what the scientific community is saying, we will be in a position to answer, I think, very relevant questions on which we need the advice of scientists,” said Andy Slaviton, a senior White House adviser. Andy Slavitt, a senior White House adviser, said.